StreetAlpha.app
Home › Stocks › MDGL

Madrigal Pharmaceuticals, Inc. (MDGL)

Healthcare
$421.99
▼ −0.46%
LAST CLOSE · NOV 17

Madrigal Pharmaceuticals develops treatments for MASH, a serious liver disease, and sells its approved medicine Rezdiffra. It last closed at $421.99 on Nov 17, down 0.46% on the day. The average 12-month price target from 4 analysts is $710.00 (+68.3% from the last close), with a high of $760.00 and a low of $633.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 3 whale options trades in MDGL, 100% of them bullish and 0% bearish. In the past 30 days there were 3 dark pool prints totaling $2.5M, the largest $976K.

AI Auto Pilots
Is MDGL in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$1.4B
+92.8% vs a year ago
Net income
−$155.5M
−10.9% margin
EPS (diluted)
−$5.35
Free cash flow
−$168.7M
−11.8% margin
Valuation
Market cap
$9.8B
23.2M shares
P/E
–
No P/E while losing money
Price to sales
6.9
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$514.6M
At Sep 30
Debt
$341.3M
At Sep 30
Shareholder equity
$626.9M
Shares outstanding
23.2M
At Oct 29
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $0$0FY2021FY2022: $0$0FY2022FY2023: $0$0FY2023FY2024: $180.1M$180.1MFY2024FY2025: $958.4M$958.4MFY2025

From MDGL's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
4firms
4 Buy0 Hold0 Sell
Each firm's latest rating on MDGL in the past 90 days
Average 12-month target
$710.00
▲ 68.3% upside

Based on 4 analysts who set a price target on MDGL in the past 90 days. The average target is $710.00, with a high of $760.00 and a low of $633.00, compared with the last close of $421.99.

Low $633.00Avg $710.00High $760.00
Blue marker: last close $421.99
Highest target$760.00
Average target$710.00
Lowest target$633.00
Latest rating changes
Canaccord GenuityTarget raised
Nov 4Buy$587 → $633
Truist SecuritiesReiterated
Nov 4Buy$743
CitigroupTarget raised
Nov 3Buy$725 → $760
Goldman SachsReinstated
Sep 24Buy$704
CitigroupInitiated
Sep 23Buy$725
DateFirmActionRatingPrice target
Nov 4Canaccord GenuityTarget raisedBuy$587 → $633
Nov 4Truist SecuritiesReiteratedBuy$743
Nov 3CitigroupTarget raisedBuy$725 → $760
Sep 24Goldman SachsReinstatedBuy$704
Sep 23CitigroupInitiatedBuy$725
Loading…

Technical Analysis

MDGL · as of the Nov 17 close · updated after every close
Downtrend

The stock is 1% below its 20 day and 12% below its 50 day average. It is 17% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 40). The nearest support is the Pivot at $420.99, and the nearest resistance the 20 day average at $427.04.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 4.9%/day
Key levels
$615.0052 week high+45.7%
$500.58100 day average+18.6%
$495.33200 day average+17.4%
$471.1350 day average+11.6%
$443.16Swing high (Nov 10)+5.0%
$428.62Pivot R1+1.6%
$427.0420 day average+1.2%
$421.99Last close
$420.99Pivot−0.2%
$414.35Pivot S1−1.8%
$353.5452 week low−16.2%
$353.54Swing low (Nov 4)−16.2%
Indicators
RSI (14)40.17Middle of its rangeNeutral
MACD-12.78Above its signal lineBullish
Stochastic54.9Middle of its rangeNeutral
ADX (14)21.6Weak trend
Williams %R-47.0Oversold below −80, overbought above −20Neutral
CCI (20)-35.5Oversold below −100, overbought above 100Neutral
Rate of change+6.5%Change over 10 sessionsBullish
ATR (14)$20.56Typical daily range, 4.9% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for MDGL

What happened before

See how MDGL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Whale flow leans bullish3 bullish and 0 bearish whale options trades in the last 90 days. See Whale Flow
November seasonalityHow MDGL usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How MDGL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2007.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
3
Bullish
3
100%
Bearish
0
0%
Date span
Sep 30 – Nov 4
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
3
Notional
$2.5M
Largest print
$976K
Loading…

MDGL Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲238 buying vs 185 selling
  • ▼Held by funds -7.3 pts
  • ▲Funds holding +25
  • ▼Superinvestors: 1 added, 4 cut
  • ▲Put/call 0.67 to 0.36
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding441416+6.0%
In funds' top 1079−22.2%
Held by funds94.9%102.2%−7.3 pts
New / increased78 / 16076 / 144+8.2%
Reduced / sold out132 / 53131 / 43+6.3%
Put/call ratio0.360.67−45.7%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See MDGL institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MDGL is in one of them and how their past MDGL trades turned out.

MDGL in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered MDGL in an article yet. Here's the latest on the wider market.

MDGL Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed May 19
Who traded MDGL · since 2023
Latest 1 filing
$1K – $15KTraded Apr 10, 2023Filed May 19, 2023
PersonTypeAmountTradedFiledDelay
Dan GoldmanD · NYSell$1K – $15KApr 10, 2023May 19, 202339 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals is a biopharmaceutical company based in West Conshohocken, Pennsylvania. It focuses on treatments for MASH, a serious liver disease that can lead to cirrhosis, liver failure and liver cancer. Its main product, Rezdiffra, is an oral medicine taken once a day for adults with moderate to advanced liver scarring who do not have cirrhosis. The company sells Rezdiffra to patients and healthcare providers in the United States and Germany, and it is developing other candidates for the disease.

Headquarters
West Conshohocken, PA